Antares Pharma to Report Third Quarter Financial and Operating Results and Host Webcast and Conference Call
November 03 2016 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release
its third quarter 2016 financial results and recent operating
progress before the market opens on Wednesday, November 9, 2016.
Management will host a webcast and conference call at 8:30 a.m. ET
(Eastern Time) on November 9, 2016 to discuss the results.
Interested parties may participate in the
conference call by dialing 1-888-280-4443 (U.S.) or 1-719-457-2653
(international) and entering access code 3270156. We encourage
interested parties to dial into the conference call at least 10
minutes prior to the scheduled start time. A replay of the
conference call will be available from 11:30 a.m. ET on Wednesday,
November 9, 2016 through 11:30 a.m. ET on Friday, December 9, 2016
by dialing 1-888-203-1112 (U.S.) or 1-719-457-0820 (international),
and entering the access code 3270156. An audio web cast and archive
of the conference call will also be available under the investor
information section of the Antares Web site at
www.antarespharma.com.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP™
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company and Teva Pharmaceutical Industries, Ltd. (Teva) recently
announced the commercial launch of VIBEX® Sumatriptan Injection USP
for the acute treatment of migraine and cluster headache in the
United States. Antares Pharma is also developing QuickShot®
Testosterone for testosterone replacement therapy. The Company's
technology platforms include VIBEX® disposable auto injectors,
disposable multi-use pen injectors and reusable needle-free
injectors. Antares Pharma has a multi-product deal with Teva that
includes VIBEX® epinephrine, exenatide multi-dose pen, and
teriparatide multi-dose pen. Our reusable needle-free injector for
use with human growth hormone (hGH) is sold worldwide by Ferring
B.V. The Company is also working with AMAG Pharmaceuticals on
a subcutaneous method of administering Makena, a progesterone
product indicated for use in lowering the risk of pre-term birth.
For more information, visit www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the timing and results of the
phase 3 studies for QuickShot® Testosterone (QST) and acceptance of
the data by the U.S. Food and Drug Administration (“FDA”); the
timing and Company’s ability to successfully complete a New Drug
Application (“NDA”) for QST, acceptance of the NDA for QST by
the FDA and approval of the same by the FDA; FDA action with
respect to Teva’s Abbreviated New Drug Application (“ANDA”) filed
for the Exenatide pen and future revenue from the same; Teva’s
ability to adequately and timely respond to the Complete Response
Letter received from the FDA for the VIBEX® epinephrine pen ANDA
and approval by the FDA of the same, the timing and therapeutic
equivalence rating thereof, and any future purchase orders and
revenue pre or post FDA approval; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; the outcome of the pending patent litigation
between Teva Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly
and Company regarding the Teriparatide multi-dose pen; the timing
and approval, if any, by the FDA of Teva’s ANDA for the
Teriparatide multi-dose pen and any future revenue resulting
therefrom; continued growth of prescriptions and sales of OTREXUP™;
the timing and results of the development project with AMAG
Pharmaceuticals for an auto injector for Makena; the timing and
results of research projects, clinical trials, and product
candidates in development; actions by the FDA or other regulatory
agencies with the respect to the Company’s products or product
candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2015, and in the Company's other periodic
reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contacts:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024